venerdì, Febbraio 23, 2024

Ritorno al futuro: allergie stagionali e gestione intelligente e consapevole del problema

Tra un mese esatto sarà primavera e ricomincerà il...

Lo abitudini di vita sono importanti per la comparsa della sindrome del colon irritabile?

La sindrome del colon irritabile (IBS) è una malattia...

Cumino nero: la spezia che mostra potenzialità curative per le malattie cardiovascolari e cerebrali

Nigella sativa: distribuzione ed usi medicinali La Nigella sativa, comunemente...

Heart MIRs in outer space: the answer stems from the marrow

University of Alabama at Birmingham researchers now report that exosomes are key to the SOS signal that the heart muscle sends out after a heart attack. The investigators say discovery of this novel pathway, a signal from the damaged heart to a systemic response by the reparative bone marrow cells, can now be leveraged to improve cell-based cardiovascular repair after heart attacks. The study, led by Dr. Gangjian Qin, professor in the UAB Department of Biomedical Engineering and director of the Molecular Cardiology Program, and Min Cheng, MD, PhD, Huazhong University of Science and Technology at Wuhan, China, is now published in the journal Nature Communications

Human cells shed exosomes. These tiny extracellular, membrane-bound vesicles can carry cargo for cell-to-cell communication, ferrying diverse loads of proteins, lipids or nucleic acids. After the heart attack, the exosomes in the bloodstream carry greatly increased amounts of heart-specific microRNAs — an observation seen in both mice and humans. These exosomes preferentially carry the microRNAs to progenitor cells in the bone marrow. Inside those progenitor cells, the microRNAs turn off a specific gene that allows the progenitor cells to leave the bone marrow and enter the bloodstream. The cells then travel to the heart to attempt repairs. For 15 years, it had been known that progenitor cells are released from the bone marrow after a heart attack. These cells move to the damaged heart muscle to attempt repairs. However, many efforts to improve that repair have yielded only modest efficacies, at best. Similarly, for a dozen years, it was known that a handful of microRNAs that are abundant in heart muscle are greatly elevated in the bloodstream after an acute heart attack, both in animals and in humans.

The UAB and Chinese researchers have now linked those two observations by identifying the cargo carrier that ferries those heart-muscle microRNAs, locating the preferred destination of the cargo carrier and describing the microRNA mechanism that releases the progenitor cells from the bone marrow. The researchers found that, after heart attack in a mouse model, levels of four heart-muscle-specific microRNAs (known as myo-miRs) were elevated 10,000- to 100,000-fold in peripheral blood after heart attack. These myo-miRs were preferentially taken up by bone marrow mononuclear cells. MicroRNAs, or miRNAs, are small, non-coding RNAs that can regulate gene expression. The human genome appears to make at least 2,000 different miRNAs. It turned out that exosomes in the blood overwhelmingly carried three of the myo-miRs after a heart attack: miR-1a, miR-208a and miR-499-5p. The fourth myo-miR, miR-133a, was partially carried by exosomes. Notably, a significant increase of circulating exosomal myo-miRs was also seen in humans after the serious heart attacks called acute ST-elevation myocardial infarction.

Exosomes from non-heart-attack mice did not carry the myo-miRs. The researchers found that both the myo-miR exosomes, from after heart attacks, and the non-heart-attack exosomes readily transferred into bone marrow mononuclear cells. It was known that blockade of a chemokine receptor called CXCR4 mediates mobilization of bone marrow progenitor cells into the blood circulation and contributes to repair of heart muscle after heart attacks. Since one of the myo-miRs showed a potential binding to the CXCR4 mRNA, all four of the myo-miRs were tested on bone marrow mononuclear cells. Surprisingly, each myo-miR alone was able to downregulate expression of CXCR4. Furthermore, exosomes from heart-attack mice downregulated CXCR4 in bone marrow mononuclear cells. Finally, researchers showed that exosomes from heart-attack mice, when transferred to intact mice, significantly reduced CXCR4 expression in bone marrow mononuclear cells and caused mobilization of progenitor cells out of the bone marrow. Thus, overall, the injured heart is signaling to mobilize the bone marrow progenitor cells.

Dr. Qin commented positively: “Our work reveals that exosomes released from the ischemic heart are in fact mediating the systemic response of bone marrow progenitor cells to the site of injury. These observations are compelling, as circulating myo-miRs are not only a biomarker, but also a functional constituent of the intricate crosstalk between the ischemic heart and the remote bone marrow organ. Because of the critical role of bone marrow progenitor cells in the ischemic tissue repair, the mechanism identified in this study could be an important component of the physiological response to ischemic injury and thus could be leveraged for treatment of ischemic heart disease”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Cheng M et al., Qin G. Nat Commun. 2019 Feb 27; 10(1):959. 

Wang W, Zheng Y et al., Li Z. Gene 2019 Mar 30; 690:75-80.

Sun XH, Wang X et al. Thromb Res. 2019 Feb 2; 177:23-32.

 

 

 

Latest

Ritorno al futuro: allergie stagionali e gestione intelligente e consapevole del problema

Tra un mese esatto sarà primavera e ricomincerà il...

Lo abitudini di vita sono importanti per la comparsa della sindrome del colon irritabile?

La sindrome del colon irritabile (IBS) è una malattia...

Cumino nero: la spezia che mostra potenzialità curative per le malattie cardiovascolari e cerebrali

Nigella sativa: distribuzione ed usi medicinali La Nigella sativa, comunemente...

Dopamina: il mediatore carente nel Parkinson che ha un ruolo più complesso di quanto creduto

Camminare è qualcosa che la maggior parte delle persone...

Newsletter

Don't miss

Ritorno al futuro: allergie stagionali e gestione intelligente e consapevole del problema

Tra un mese esatto sarà primavera e ricomincerà il...

Lo abitudini di vita sono importanti per la comparsa della sindrome del colon irritabile?

La sindrome del colon irritabile (IBS) è una malattia...

Cumino nero: la spezia che mostra potenzialità curative per le malattie cardiovascolari e cerebrali

Nigella sativa: distribuzione ed usi medicinali La Nigella sativa, comunemente...

Dopamina: il mediatore carente nel Parkinson che ha un ruolo più complesso di quanto creduto

Camminare è qualcosa che la maggior parte delle persone...

I fattori socioeconomici e relazionali come influenti sul benessere e la salute mentale

La salute mentale è fondamentale per il benessere individuale,...
Dott. Gianfrancesco Cormaci
Dott. Gianfrancesco Cormaci
Laurea in Medicina e Chirurgia nel 1998, specialista in Biochimica Clinica dal 2002, ha conseguito dottorato in Neurobiologia nel 2006. Ex-ricercatore, ha trascorso 5 anni negli USA alle dipendenze dell' NIH/NIDA e poi della Johns Hopkins University. Guardia medica presso la casa di Cura Sant'Agata a Catania. In libera professione, si occupa di Medicina Preventiva personalizzata e intolleranze alimentari. Detentore di un brevetto per la fabbricazione di sfarinati gluten-free a partire da regolare farina di grano. Responsabile della sezione R&D della CoFood s.r.l. per la ricerca e sviluppo di nuovi prodotti alimentari, inclusi quelli a fini medici speciali.

Pet therapy: come migliora l’umore e allevia l’ansia e lo stress nei bambini

Da tempo si è intuito che i bambini che soffrono di stress che interagiscono con i cani da terapia beneficiano di un miglioramento dell’umore...

Sclerosi multipla: i solventi come fattore di rischio lavorativo ad impatto elevato

La sclerosi multipla (SM) è una malattia infiammatoria cronica che si pensa affligga circa 400.000 persone negli Stati Uniti e 2,1 milioni di persone...

Lotta al lupus sistemico: aggiornamento dai congressi con afimetoran ed altre molecole rivoluzionarie

Il lupus è una malattia autoimmune che attacca gli organi e può essere fatale. Non esiste una cura, quindi i trattamenti attuali mirano a...